David Scheinberg joins Galena's SAB
This article was originally published in Scrip
Galena Biopharma, a biotech company developing targeted oncology treatments, has appointed Dr David Scheinberg to its scientific advisory board. Dr Scheinberg is Memorial Sloan-Kettering Cancer Center's Vincent Astor chair, chair of the Molecular Pharmacology and Chemistry Program in the Sloan-Kettering Institute, and chair of the Experimental Therapeutics and the Nanotechnology Centers at Memorial Sloan-Kettering. In addition, Dr Scheinberg is professor of medicine and pharmacology at Weill-Cornell Medical College and serves on the boards of Progenics and Contrafect, and the scientific advisory boards of Actinium Pharmaceuticals, Ensysce Biosciences and OncoPep.